Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.

Ther Adv Chronic Dis

Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center, School of Medicine, Iran University of Medical Sciences, Rasool Akram Medical Complex, Sattarkhan Avenue, Niayesh Street, Tehran 1449614535, Iran.

Published: May 2024

AI Article Synopsis

  • Hidradenitis suppurativa (HS) is a challenging inflammatory skin condition with limited treatment options, and traditional TNF-α inhibitors often show insufficient efficacy.
  • Recent studies have explored the effectiveness of newer anti-TNF drugs, certolizumab pegol (CPZ) and golimumab, suggesting they might be beneficial for patients refractory to existing treatments.
  • A review of multiple studies indicates that both CPZ and golimumab demonstrated safety and efficacy in managing moderate-to-severe HS, particularly in individuals who did not respond to other therapies like adalimumab.

Article Abstract

Hidradenitis suppurativa (HS) is an inflammatory skin condition with an underlying inflammatory process. Due to the limited efficacy of available treatments, HS remains a therapeutic challenge. The safety and efficacy of tumor necrosis factor-α (TNF-α) inhibitors, adalimumab, infliximab, and etanercept, are well studied in this patient population, and in some cases, HS was unresponsive to them. In recent years, evidence has been growing regarding the application of other anti-TNFs, including certolizumab pegol (CPZ) and golimumab. We sought to evaluate the overall safety and efficacy of golimumab and CPZ in the management of HS. A comprehensive search was performed on the PubMed, Scopus, Web of Science, and Ovid Embase databases, as well as the Google Scholar search engine from initiation to 31 August 2023. A total of nine and four studies used CPZ and golimumab to treat HS, respectively. Individuals with concomitant inflammatory immune-mediated diseases, pregnant females, and patients who were refractory to previous treatments achieved a Hidradenitis Suppurativa Clinical Response following CPZ administration. Also, golimumab showed promise in treating recalcitrant HS after the failure of other treatments, such as adalimumab and anti-interleukin-1. CPZ and golimumab can be efficacious treatment options for moderate-to-severe HS, especially in patients who are unresponsive to other TNF inhibitors, such as adalimumab.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11143857PMC
http://dx.doi.org/10.1177/20406223241257342DOI Listing

Publication Analysis

Top Keywords

hidradenitis suppurativa
12
cpz golimumab
12
certolizumab pegol
8
safety efficacy
8
inhibitors adalimumab
8
golimumab
6
cpz
5
golimumab certolizumab
4
pegol treatment
4
treatment hidradenitis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!